Shareholder Tools

Investor Relations

Investor Relations

NASDAQ: ECYT
$1.40 0.00
Sep 25, 2017 at 4:00 PM ET
Intraday data provided by eSignal

Corporate Profile

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

In addition, the Company continues to pursue applications of the SMDC platform and is working to bring assets toward clinical development in several areas, including EC2629, its dual-targeted DNA crosslinker drug that can attack both tumor associated macrophages (“TAMs”) and cancer cells, and its chimeric antigen receptor T-cell (“CAR T-Cell”) SMDC adaptor platform.

Press ReleasesView All

Endocyte to Present at the 2017 Cantor Global Healthcare Conference
WEST LAFAYETTE, Ind., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugate...

Read More

Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
- Poster further demonstrates the potential of Endocyte's SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors - - Unwante...

Read More